Portal de Periódicos da CAPES

Elevated amylase in plasma represents an adverse prognostic marker in patients with metastatic pancreatic cancer

2018; Springer Science+Business Media; Volume: 130; Issue: 19-20 Linguagem: Inglês

10.1007/s00508-018-1383-3

1613-7671

Eva Asamer, Joanna Szkandera, Paul Gibiser, Anna L. Lembeck, Tatjana Stojaković, Peter Kornprat, C. Lackner, Thomas Winder, Konstantin Schlick, Herbert Stöger, Armin Gerger, Martin Pichler, Michael Stotz,

Renal cell carcinoma treatment

The aim of this study was to investigate the prognostic relevance of plasma amylase and lipase concerning survival of patients suffering from metastatic pancreatic cancer (PC).This retrospective study included 351 patients with metastatic PC, who were treated in a single academic institution. Cancer-specific survival (CSS) was analyzed using the Kaplan-Meier method. To further evaluate the prognostic significance of lipase and amylase, univariate and multivariate values were calculated using Cox proportional models.In univariate analysis, an increased amylase level was associated with shorter CSS in PC patients (hazard ratio HR = 1.258; 95% confidence interval CI = 1.011-1.566; p = 0.039). In multivariate analysis, including gender, age, CA19-9 and administration of chemotherapy, increased amylase levels prevailed as an independent prognostic factor for CSS (HR = 1.373; 95%CI = 1.004-1.878; p = 0.047).Plasma amylase was found to be an independent prognostic factor in patients with metastatic PC. The results indicate that amylase might represent a novel and useful marker for better patient stratification in PC management.